AcelRx Pharmaceuticals Inc. recently presented
the subgroup analysis from the SAP301 clinical study by board-certified plastic
surgeon and AcelRx clinical investigator Dr. Shankar Lakshman at the American
Society of Plastic Surgeons (ASPS) annual meeting.
The SAP301 Phase 3 clinical study compared ARX-04 to a placebo
for the treatment of patients with moderate-to-severe acute pain after
undergoing ambulatory abdominal surgery.
The presentation by Dr. Lakshman featured the activity of ARX-04
that was observed in 80 of the 161 patients who took part in the study who had
abdominoplasty surgery in which ARX-04 showed a substantial statistical improvement
in patients over placebo, which helped the study meet its primary goal in
effectiveness.
The presentation took place on Sept. 24 and was titled “Phase 3 Results of Sublingual Sufentanil 30 mcg
for the Management of Post-Operative Pain Following Abdominoplasty Surgery.”
The authors of the presentation are Dr. Lakshman of Pasadena
Surgeons in Pasadena, California; Dr. Harold Minkowitz, Memorial Hermann
Memorial City Medical Center in Houston, Texas; Dr. Timothy Melson, Helen Keller
Hospital in Sheffield, Alabama; and Dr. David Leiman, Victory Medical Center in
Houston, Texas.
AcelRx presents SAP301 data at annual ASPS meeting
Alerts Sign-up